Inovio Gets Accelerated Approval For Rare HPV-Related Respiratory Disease
Inovio sets a $460,000 list price for a full course of Voceryq, its first approved DNA medicine and the second approved to treat recurrent respiratory papillomatosis.
Scrip - November 2, 2026

LIB Keeps Anti-PCSK9 Pricing Competitive As Lerochol Autoinjector Launch Nears
LIB Therapeutics will launch its autoinjector for once-monthly Lerochol (lerodalcibep), available now in a prefilled syringe, with a $300 monthly list price – the lowest of the PCSK9 inhibitor class.
Scrip - November 2, 2026

AstraZeneca’s Etcamah Priced In Line With Oral SERD Market
The company declined to publicly disclose the price of the new breast cancer treatment, but the US WAC is $24,392 for a monthly supply, according to a filing with the Vermont Attorney General.
Scrip - November 2, 2026

In Wake Of Lackluster Trial Results, Karyopharm To Merge With Ayrmid
The company said it would file for bankruptcy under Chapter 11 and merge with the UK-based parent company of Gamida Cell.
Scrip - November 2, 2026

ESMO 2026: Where Next For Moderna And Merck’s Cancer Vaccine?
The success of the first Phase III trial of Moderna/Merck & Co.’s intismeran autogene at ESMO has sparked questions over the place of the pioneering individualized vaccine on the melanoma treatment pathway and beyond.
Scrip - November 2, 2026

Van Naarden On Lilly’s Dealmaking: There’s Plenty More To Come
The company’s head of business development looks back over a remarkably active dealmaking year – and said its less eye-catching transactions might turn out to be the biggest hits.
Scrip - November 2, 2026

Sun Banks On Unloxcyt’s Keytruda Parity, Ilumya Expansion To Beat Innovation Portfolio Dampening
Sun Pharma is counting on a label expansion for Ilumya, a NCCN upgrade for Unloxcyt in the US and a lerodalcibep license in ex-US and China markets to unlock additional sales.
Scrip - November 2, 2026

Brainomix Pitches Quantitative CT To Fibrosis Trial Sponsors As Boehringer Partnership Deepens
Brainomix is pitching its e-Lung quantitative CT software to fibrosis trial sponsors after INBUILD data showed it detected nintedanib’s effect, and with Boehringer naming it a co-primary endpoint in the Phase IIIb DROP-FPF trial. FVC remains the regulatory standard.
Scrip - November 2, 2026

Alzheimer’s And Neurodegeneration Are Forcing System-Wide Change
Earlier detection is reshaping how Alzheimer’s trials are designed and conducted
Scrip - November 2, 2026

Why Early Evidence Strategy Matters for Emerging Biotechs
Building a stronger evidence strategy to inform development decisions and demonstrate long-term value
Scrip - November 2, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026

False-Negative Risk Prompts Class I Recall Of Werfen’s HemosIL AcuStar HIT Test
The FDA has classified Werfen’s recall of four lots of its HemosIL AcuStar HIT diagnostic test as Class I after performance issues raised concerns about false-negative results that could delay diagnosis of a potentially life-threatening blood-clotting disorder.
Medtech Insight - November 2, 2026

Opinion: CMS Can Make RAPID A Win For Patients And American Medtech Innovation
RAPID could speed Medicare access to breakthrough medtech, but CMS and FDA should add firm milestones, adequate staffing and flexible eligibility, including for Class II devices. Those refinements would give start-ups the predictability they need and get proven technologies to patients sooner.
Medtech Insight - November 2, 2026

Brainomix Says Biomarker Qualification Is Next Step For Its FDA-Cleared Lung AI Software
Quantitative CT from two platforms, Brainomix’s e-Lung and a UCLA algorithm, both detected nintedanib’s effect in the Phase III INBUILD substudy. Brainomix’s Peter George said e-Lung’s reticulovascular score alone predicted later mortality, but FVC remains the regulator’s primary endpoint.
Medtech Insight - November 2, 2026

TCT 2026: Elixir DynamX Bioadaptor Pulls Ahead of DES After 6 Months In Pooled Patient Analysis
Elixir Medical’s first individual patient data analysis from 2,885 patients of its two randomized trials points to a sustained advantage over Medtronic’s Resolute Onyx, especially in ACS and LAD lesions.
Medtech Insight - November 2, 2026

TCT 2026: 12-Month Data Show Heartflow’s CT-Guided PCI Planning Matches Invasive IVUS Outcomes
At TCT, Heartflow announced 12-month data from its late-breaking P4 study showing that CT-guided planning was non-inferior to intravascular ultrasound guidance with a 17-minute cut in procedure time and 12% reduction in contrast volume.
Medtech Insight - November 2, 2026

Illumina Lifts 2026 Outlook As NovaSeq X Placements Rise But Instrument Revenue Slips
Illumina raised its 2026 revenue and EPS guidance after clinical demand and 80-plus NovaSeq X placements lifted third-quarter results above forecast. But instrument revenue was held back by discounting and leasing, leaving consumables to carry the case for high-single-digit growth in 2027.
Medtech Insight - November 2, 2026

FDA Issues Revised Draft Guidance On Essential Drug Delivery Performance Characteristics
Revised draft guidance from US FDA’s Office of Combination Products and its drug, device and biologics centers recommends how sponsors should identify, verify and control the system-level characteristics meant to ensure a drug-device product delivers the intended dose.
Medtech Insight - November 2, 2026

Pulling Oil Rinse Brand Pulls Challenged Claims
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026

Carpe Deodorant Ad Claims For Price Discounts, Superior Performance Sweat Under P&G Challenge
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026

Sun Expects Organon Acquisition Closure In Q4, India Gains Offset Lenalidomide Slide In Q2
Sun Pharma saw its Q2FY27 US formulation sales decline with falling lenalidomide sales, but the Organon acquisition closure in the fourth quarter, new product launches and continued India business growth are expected to lend support in the second half.
Generics Bulletin - November 2, 2026

MS Pharma Partners With Adcan Pharma To Build Biosimilar Resilience In United Arab Emirates
MS Pharma signs a strategic collaboration deal with Adcan Pharma, advancing pharmaceutical localization, especially biosimilars, in United Arab Emirates.
Generics Bulletin - November 2, 2026

Fresenius Ups The Ante In Biosimilars With 37-Product WuXi Collaboration
Billed as “the largest development agreement announced in the biosimilars industry to date,” Fresenius Kabi has announced a deal with WuXi Biologics for exclusive option rights for up to 37 “potential first-to-market” biosimilar candidates, more than doubling its existing pipeline.
Generics Bulletin - November 2, 2026

A New Generation Of Stroke Drugs Targets The Damage Left Behind
After the 2000s neuroprotection failures, stroke drug development is reviving. Scp776 (IGF-1) and loberamisal show early efficacy signals, DDL-930 and maraviroc target recovery, and nerinetide’s 2025 miss shows the risk remains high.
In Vivo - November 2, 2026